Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Aiming To Challenge Pfizer In Cardiomyopathy

Alnylam building
Alnylam is depending on the trial to expand into treating ATTR cardiomyopathy patients. • Source: Alamy

More from Business

More from Scrip